GL1X · GenesisL1 explorer

Research workbench

P38507: AlphaFold monomer V2.0 prediction for immunoglobulin G-binding protein a (P38507)

Analyse P38507: AlphaFold monomer V2.0 prediction for immunoglobulin G-binding protein… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

Accession
P38507
Type
protein
Length
508 residues
Chains
1
Deposited
09-DEC-21
Collection
MolNFT v1 / AlphaFold
Contract
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
Owner
0x40B9C9d5F084D34d026E9d5Dd10501AcdF6d6152
Molecule
Immunoglobulin G-binding protein a
UniProt
P38507
Pockets
2 · best druggability 0.37

Structure

1 distinct chain · 44% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AImmunoglobulin G-binding protein aprotein50844% helix, 1% strandP38507

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11110.370.7415empty
2700.280.7211empty

Compared structures

  • 8CPL · YZw2 a scaffold for cryo-EM of small proteins of interest · an experimental structure of the same protein · chain A against C, TM-score 0.25
  • 5H7D · Crystal structure of the YgjG-protein A-Zpa963-calmodulin complex · an experimental structure of the same protein · chain A against C, TM-score 0.24
  • 5X3F · Crystal structure of the YgjG-Protein A-Zpa963-PKA catalytic domain · an experimental structure of the same protein · chain A against A, TM-score 0.23
  • 8R2P · YZwIdeal x16 a scaffold for cryo-EM of small proteins of interest crystallizing in space… · an experimental structure of the same protein · chain A against D, TM-score 0.22
  • 5H7C · Crystal structure of a repeat protein with two Protein A-DHR14 repeat modules · an experimental structure of the same protein · chain A against A, TM-score 0.21

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.